Trial Profile

A Retrospective, Multicenter, Cohort Study To Assess Efficacy of Therapies After Venetoclax Discontinuation in Patients with Chronic Lymphocytic Leukemia Focusing On Cellular Therapies and B-cell Receptor Transduction Inhibitors

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; CAR-T cell therapies (Primary) ; Duvelisib (Primary) ; Ibrutinib (Primary) ; Idelalisib (Primary) ; Obinutuzumab (Primary) ; Ofatumumab (Primary) ; Rituximab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use

09 Dec 2019 New trial record
06 Nov 2019 Primary endpoint, Overall Response Rate (ORR) in BTKi naive vs. exposed patients has been met.
06 Nov 2019 Results, assessing efficacy of therapies after discontinuation of Venetoclax focusing on cellular therapies and B-cell receptor transduction inhibitors in patients with Chronic Lymphocytic Leukemia, released at the 61st Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com